Sunil Pancholi

• Oversee all aspects of operational functions for research and development activities within the company • Planning and managing the relocation of iosBio to new, larger premises allowing expansion of functional capabilities

• Lead the Cell Biology Team in the Process Development section, undertaking process validation of prospective vaccine candidates. • Involved in formulation and CMC strategies for oral administration

• Initiation of new functional technologies in the company. • Development of platelet-rich plasma (PRP) as a saleable product for use in veterinary health • Isolation and characterisation of mesenchymal stem cells (MSCs) derived from umbilical cord tissue, amniotic membrane and chorion for commercial uses • Validation of tissue processing/storage for umbilical cord/placental tissue banking for the HTA • Clean room production of the proprietary blood separation product TotiCyte, a CE marked medical device, to GMP standards and QC validation of the finished product

• Responsible for all aspects of the efficient set-up, transition and operation of 2 laboratories including budgets, resource management, procurement, health & safety, disaster contingency • Overseeing and directing 7 staff members • Involved in staff recruitment and training • Responsible for experimental design, data acquisition, analysis and interpretation • Worked extensively with industrial collaborators (AstraZeneca, Novartis, Pfizer, GSK, Johnson & Johnson, PUMA Biotechnology, Radius Health, H3 Biomedicine & Orion Pharma) to produce preclinical data on small molecule inhibitors, examine mode of action (MOA) and advise on novel potential drug combinations • Preclinical data from several projects allowed patient stratification & biomarker identification and directly translated into the design and initiation of clinical trials (PALOMA-3, BOLERO-2, SoFEA) • Generated in vitro cellular models of resistance to tamoxifen, aromatase inhibitors, CDK4/6 inhibitors, CDK7 inhibitors and SERDs, resulting in one of the world’s largest collections • Regular participant in fundraiser tours of the laboratory facilities involving explaining research ideas and concepts to a lay audience

The role of senescent fibroblasts in aged skin pathology: • Led a collaborative project with a company developing surgical implants for dermal wounds • Developed both in vitro and in vivo approaches to examine whether the age of cells or of the extracellular matrix are responsible for the pathological changes associated with dermal ageing • Reconstructed dermal tissue models were generated using young and aged cells and were used to examine growth capacity, invasive ability and secretion in young and old extracellular matrices • Established an in vivo model to study these differences in collaboration with the University of Dundee. The model enabled the study of cell invasion and revascularisation/angiogenesis to be determined in the whole animal • Responsible for supervising 3 junior staff members

Vascular integrity in response to dietary perturbation and senescence: • Worked in a multi-disciplinary team (25 staff) consisting of scientists, clinicians and nursing staff • Established and ran a tissue culture laboratory to provide a working facility for the whole department • Responsible for supervising and mentoring 4 junior research staff members • Investigated the effects of metabolic perturbation on vascular cell growth and phenotype